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BMK1 is activated in glomeruli of diabetic rats and in mesangial
cells by high glucose conditions.
Background. High glucose causes renal cell injury through
various signal transduction pathways, including mitogen-
activated protein (MAP) kinases cascades. Big MAP kinase 1
(BMK1), also known as extracellular signal-regulated kinase
5 (ERK5), is a recently identified MAP kinase family mem-
ber and was reported to be sensitive to osmotic and oxidative
stress. However, the role of BMK1 in diabetic nephropathy has
not been elucidated yet.
Methods. We investigated whether BMK1 is activated in the
glomeruli of Otsuka Long Evans Tokushima Fatty (OLETF)
rats, a model of type 2 diabetes mellitus in comparison with
the control Long Evans Tokushima Otsuka (LETO) rats. We
also examined the effect of high glucose on BMK1 activity in
cultured rat mesangial cells.
Results. BMK1 and ERK1/2 but not p38 were activated in the
glomeruli of OLETF rats, which showed diabetic nephropa-
thy at 52 weeks of age. High glucose, in addition to a high
concentration of raffinose, caused rapid and significant acti-
vation of BMK1 in rat mesangial cells. MAP kinase/ERK ki-
nase (MEK) inhibitors, U0126 and PD98059, both inhibited
BMK1 activation by high glucose in a concentration-dependent
manner. Protein kinase C (PKC) inhibition by GF109203X and
PKC down-regulation with long-time phorbol myristate acetate
(PMA) treatment both inhibited BMK1 and Src kinase activa-
tion. Src kinase inhibitors, herbimycin A and PP2, also inhib-
ited high glucose-induced BMK1 activation. PKC inhibitors,
Src inhibitors and MEK inhibitors, all inhibited cell prolifera-
tion by high glucose. Finally, transfection of dominant-negative
MEK5, which is an upstream regulator of BMK1, abolished the
BMK1-mediated rat mesangial cell proliferation stimulated by
high glucose.
Conclusion. In the present study, we demonstrated that high
glucose activates BMK1 both in vivo and in vitro. It was sug-
gested that high glucose induces PKC- and c-Src-dependent
BMK1 activation. It could not be denied that BMK1 activa-
tion is induced through an osmotic stress-sensitive mechanism.
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BMK1-mediated mesangial cell growth may be involved in the
pathogenesis of diabetic nephropathy.
Diabetic nephropathy is the most common cause of
end-stage renal failure in patients starting dialysis in de-
veloped countries [1]. Clinical trials have demonstrated
that high glucose is the principal cause of renal damage
in both type 1 [2] and type 2 diabetes [3]. Although the
underlying genetic predisposition to this microvascular
complication remains elusive, an investigation of the cel-
lular and molecular mechanisms was performed. Many
studies reported that various renal cell types cultured
in high glucose medium or stimulated by high glucose
exhibit the typical features of cellular hypertrophy, cell
proliferation, and excessive production of extracellular
matrix (ECM) that are characteristic of diabetic
nephropathy. Altered mesangial cell function in high glu-
cose exposure plays a central role in the pathogenesis of
progressive diabetic glomerulopathy. Activation of pro-
tein kinase C (PKC) is one of the major mechanisms in-
volved in high glucose-induced glomerular injury [4] and
produces reactive oxygen species (ROS) and subsequent
lipid peroxidation [5–8]. High glucose generates ROS as a
result of glucose auto-oxidation, metabolism, and forma-
tion of advanced glycosylation end products [8]. All these
signaling molecules involved into mitogen-activated pro-
tein (MAP) kinase signaling pathways in glomerular
cells [9]. High glucose-induced diabetic complications
have been implicated, in part, to the activation of MAP
kinases [9].
Four subfamilies of MAP kinases that are activated
by high glucose have been identified as follows: extracel-
lular signal-regulated kinase 1/2 (ERK1/2), c-Jun NH2-
terminal kinase (JNK), p38 kinase, and big MAP kinase
1 (BMK1 or ERK5) [10, 11]. Each subfamily may be
regulated via different signal transduction pathways and
modulate specific cell functions [12]. BMK1 was recently
identified as a MAP kinase family member with a large
COOH terminal and a unique loop-12 sequence that
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shares the TEY activation motif with ERK1/2 but is
activated by MAP kinase/ERK kinase 5 (MEK5) [13,
14]. BMK1 was reported to be activated by serum, epi-
dermal growth factor (EGF), and nerve growth factor,
oxidative stress, and osmotic stress in various cells. How-
ever, the role of BMK1 in diabetic nephropathy and high
glucose-induced BMK1 activation in mesangial cells have
not been reported yet. Since high glucose causes osmotic
stress and produces ROS in mesangial cells, BMK1 may
be involved in diabetic nephropathy. Therefore, we hy-
pothesized that BMK1 may be activated by high glu-
cose in mesangial cells which may play a role in diabetic
nephropathy.
In the present study, we first investigated whether
BMK1 is activated in the glomeruli of Otsuka Long Evans
Tokushima Fatty (OLETF) rats, a model of type 2 dia-
betes mellitus, compared to its age-matched control Long
Evans Tokushima Otsuka (LETO) rats. Thereafter, we
examined the effect of high glucose on the change in
BMK1 activity in cultured rat mesangial cells. Further-
more, we investigated the signaling pathways that are in-
volved in BMK1 activation and their pathophysiologic
implications in high glucose-induced cellular injury.
METHODS
Animals and reagents
All procedures were in accordance with institu-
tional guidelines for animal research. Age-matched male
OLETF rats and control male LETO rats were provided
by Otsuka Pharmaceutical Co., Ltd. (Tokushima, Japan).
They were fed standard laboratory chow and given tap
water ad libitum. Kidney samples were harvested at the
end of 52 weeks of age in both OLETF and LETO rats.
The left kidney was perfused with chilled saline solu-
tion and snap-frozen in liquid nitrogen and stored at
−80◦C until processed for cortex protein extraction and
analysis for immunofluorescence staining with phospho-
BMK1/ERK5 antibody. The right kidney was perfused
with chilled saline solution and fixed in 10% buffered
paraformaldehyde for histologic examination. All mate-
rials were purchased from Sigma except where indicated.
Herbimicyn A and PP2 were purchased from Calbiochem
(San Diego, CA, USA). U0126 was from Promega (Madi-
son, WI, USA). PD98059, GF109203X, and phorbol
myristate acetate (PMA) were from Wako Pure Chem-
ical Industries, Ltd. (Osaka, Japan). Anti-ERK5 and
anti-ERK1/2 antibody were from Santa Cruz Biotech-
nology (Santa Cruz, CA, USA). Anti-phospho-BMK1/
ERK5 antibody was from Upstate Biotechnology, Inc.
(Lake Placid, NY, USA). Anti-p38 antibody, anti-
phospho-p38 antibody and anti-phospho-ERK1/2 anti-
body were from Cell Signaling Technology (Beverly, MA,
USA). Anti-Src antibody was from Upstate Biotechnol-
ogy. Anti-Src phospho-specific antibody (Tyr418) was
from Biosource (Camarillo, CA, USA). All other ma-
terials were commercial products of reagent grade.
Histology and immunohistochemistry
Kidney tissues from both OLETF and LETO rats were
processed and examined by light microscopy and im-
munofluorescence staining as previously described [15].
For evaluation of mesangial matrix accumulation and
glomerular hypercellularity, the kidneys were fixed with
10% buffered paraformaldehyde (pH 7.4), embedded in
paraffin, sectioned into 3 lm slices, and stained with pe-
riodic acid-Schiff (PAS) reagent. At least 30 glomeruli
were observed to evaluate the severity of glomerular
injury. For immunofluorescence staining with phospho-
BMK1/ERK5 antibody, 3 lm slices of frozen sections
were fixed in acetone. They were then incubated with the
sheep anti-BMK1/EKR5 antibody for 1 hour and subse-
quently with fluorescein isothiocyanate (FITC)-coupled
donkey antisheep IgG antibody (Jackson ImmunoRe-
search Laboratories, Inc., West Grove, PA, USA). As
a control, kidney sections were incubated with non-
immune sheep serum or unrelated goat IgG antibody,
followed by FITC-coupled secondary antibody. These
controls gave entirely negative results. Immunofluores-
cence was visualized using a fluorescent microscope
(Olympus, Tokyo, Japan). For semiquantitative evalua-
tion of glomerular hypercellularity and mesangial matrix
accumulation, all 3 lm PAS-stained sections were coded
and read by a blinded observer. At least 30 glomeruli were
selected at random, cell nuclei were counted, and the
degree of glomerular matrix expansion was determined
using a published method [15]. The percentage of each
glomerulus occupied by mesangial matrix was estimated
and assigned a code as follows: 0, no localized increase
of glomerular mesangial matrix; 1, segmental increase of
mesangial matrix with less than 25% of glomerular tuft;
2, segmental increase of mesangial matrix with 25% to
50% of glomerular tuft; 3, increase of mesangial matrix
with 50% to 75% of glomerular tuft; and 4, increase of
mesangial matrix with more than 75% of glomerular tuft.
Cell culture and transfection
Rat mesangial cells were obtained from intact
glomeruli of 4- to 6-week-old Sprague-Dawley rats and
characterized according to published methods [16]. Rat
mesangial cells were used between passages 5 and 15
and were maintained in 199 medium supplemented with
18% fetal bovine serum (FBS) and antibiotics (100 U/mL
penicillin and 100 lg/mL streptomycin) in tissue culture
flasks. In this medium, the glucose concentration was
5.5 mmol/L. The cultures were maintained in a humid-
ified atmosphere containing 5% CO2 at 37◦C. The cells
were then removed from the flasks with 0.05% trypsin
plus 0.01% ethylenediaminetetraacetic acid (EDTA) and
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seeded onto 35 mm or 100 mm dishes. Cells at 70% to
80% confluence were growth arrested by incubation in
serum-free 199 medium for 24 to 48 hours prior to use.
All experiments except methyl-thiazolyl tertrazolium
(MTT) assay were performed with growth-arrested cells
to minimize basal BMK1 activity. For transfection, the
constitutive-active MEK5 (CA-MEK5) or the dominant-
negative MEK5 (DN-MEK5) forms of MEK5 was used
in 30% to 50% confluent rat mesangial cells. Each plas-
mid DNA was provided by Dr. Eisuke Nishida of Kyoto
University [17]. CA-MEK5 and DN-MEK5 were sub-
cloned into a plasmid pcDL-SRa. For transient expres-
sion experiments, cells were transfected with SuperFector
(B-Bridge International, Inc., San Jose, CA, USA) in re-
duced serum OPTI-minimal essential medium I (OPTI-
MEM I) (Invitrogen Corporation, Carlsbad, CA, USA)
for 5 hours. After transfection, cells were replaced with
199 medium supplemented with 18% FBS and antibi-
otics. After 24 hours of incubation with or without the
addition of 10 mmol/L glucose (final concentration was
15.5 mmol/L), cells were used for experiments of MTT
assay.
Protein extraction
For in vivo experiments, renal cortex of both OLETF
and LETO rats were excised and homogenized in lysis
buffer [20 mmol/L Tris-HCl, pH 7.4, 150 mmol/L NaCl,
1 mmol/L Na2EDTA, 1 mmol/L ethyleneglycol tetraac-
etate (EGTA), 1% Triton, 2.5 mmol/L sodium pyrophos-
phate, 1 mmol/L b-glycerophosphate, 1 mmol/L Na3VO4,
1 lg/mL leupeptin and 1 mmol/L phenylmethylsulfonyl
fluoride (PMSF)]. For in vitro experiments, subconfluent
rat mesangial cells in 100 mm culture dishes were made
quiescent by placing them in serum-free medium. Rat
mesangial cells in the serum-free medium were treated
with or without stimulation: each indicated time or dose-
point. After stimulation, the cells were treated with
0.5 mL of lysis buffer and flash frozen on liquid nitro-
gen. After allowing the cells to thaw, cells were scraped
off the dish and both the samples of rat mesangial cells
protein extract and renal cortex were sonicated (Sonifier
250; Branson Ultra-Sonics Co., Danbury, UK) on ice for
1 minute. Then, the samples were centrifuged at 14,000g
(4◦C for 30 minutes) and the protein concentration was
determined using the Bradford protein assay (Bio-Rad,
Hercules, CA, USA) and stored at −80◦C until the pro-
tein kinase assay.
Immunoprecipitation kinase assay of BMK1
For immunoprecipitation, protein extraction samples
were incubated with 10 lg of anti-ERK5 antibody (Santa
Cruz Biotechnology) overnight and then incubated with
protein A agarose beads for 3 hours on a roller system
at 4◦C. After immunoprecipitation, samples were eval-
uated with Western blot analysis using phospho-specific
antibody for BMK1, ERK5 as described previously
[18]. For Western blot analysis, samples were boiled for
5 minutes in Laemmli sample buffer and were subjected
to 7% sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE), samples were then trans-
ferred to a nitrocellulose membrane (HybondTM-ECL;
Amersham Pharmacia Biotech, Buckinghamshire,
England). Complete protein transfer to the membrane
was verified by staining the gel with Coommasie blue.
The membrane was blocked for 1 hour at room tem-
perature with 5% bovine serum albumin (BSA) in
phosphate-buffered saline-Tween 20 (PBS-T). The blots
were incubated overnight at 4◦C with anti-BMK1/ERK5
phospho-specific antibody (Upstate Biotechnology),
followed by incubation for 1 hour with antisheep sec-
ondary antibody (horseradish peroxidase-conjugated).
Immunoreactive bands were visualized using enhanced
chemiluminescence (ECL) with ECL reagent (Amer-
sham Pharmacia Biotech) treatment and exposure to
Hyperfilm-ECL. The intensity of the bands was mea-
sured using a Macintosh computer (Apple Computer,
Inc.) with an optical scanner (Epson GT-8000; Seiko,
Tokyo, Japan), using the public domain NIH Image
program.
Western blot analysis for ERK1/2, p38,
and Src kinase activations
ERK1/2, p38, and Src kinase activities were measured
with Western blot analysis as described previously [18].
ERK1/2 and p38 kinase activities were measured in the
protein of the renal cortex of both OLETF and LETO
rats. Src kinase was measured in the protein of rat mesan-
gial cells. For evaluation of activated ERK1/2, p38, and
c-Src, phospho-specific ERK1/2 antibody, phospho-
specific p38 antibody (Cell Signaling Technology) and
phospho-specific Src antibody at Tyr418 (Biosource),
were used, respectively. For Western blot analysis, the
renal cortex or protein extract (30 lg) of rat mesan-
gial cells was boiled for 5 minutes in Laemmli sample
buffer and then subjected to SDS-PAGE, and the protein
extracts were transferred to a nitrocellulose membrane
(HybondTM-ECL; Amersham Pharmacia Biotech). The
membrane was blocked for 1 hour at room tempera-
ture with 5% BSA in PBS-T. The blots were incubated
overnight at 4◦C with phospho-ERK1/2, phospho-p38
or phospho-Src antibody, followed by incubation for
1 hour with secondary antibody (horseradish peroxidase-
conjugated). Visualization of immunoreactive bands and
measurement of band intensity were performed by the
methods for immunoprecipitation kinase assay of BMK1.
PKC activity assay
PKC activity was measured with the Pep Tag
assay system (Promega), in which the change in
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charge of a fluorescent-tagged PKC-specific substrate
(PLSRTLSVAAK), which occurs with phosphorylation,
is detected by separation on agarose gel electrophoresis
at a natural pH [19]. At the end of the incubation pe-
riod, the rat mesangial cells were washed with Hanks’
balanced salt solution containing 1 mmol/L PMSF and
1 lmol/L leupeptin, placed in the same buffer, and then
frozen-thawed for lysis. Aliquots were taken for the assay,
which was performed according to the manufacturer’s
instructions.
Cell proliferation determination with MTT assay
The MTT assay measures the functional activity of mi-
tochondrial dehydrogenase [20]. MTT is a yellow-colored
tetrazolium salt which is reduced to purple formazan cor-
responding to the reduction reaction products with con-
comitant oxidation of nicotinamide adenine dinucleotide
(NADH) and the reduced form of nicotinamide ade-
nine dinucleotide phosphate (NADPH). Measurements
of cellular MTT reduction were carried out as described
previously [21]. Rat mesangial cells were cultured at 30%
to 50% confluency. After serum starvation with serum-
free 199 medium, cells were incubated in a serum- and
antibiotic-free OPTI-MEM I (Invitrogen Corporation)
for transfection experiments. Following the indicated in-
cubation time with glucose, MTT was added to a final
concentration of 0.5 mg/mL, and after a further 1 hour in-
cubation rat mesangial cells were lysed with isopropanol
that contained 0.04 N HCl. MTT reduction was read at
550 nm using a spectrophotometer.
Statistics
Values are presented as mean ± SD for five separate ex-
periments. One-way analysis of variance (ANOVA) was
used to determine significance among groups, after which
the modified t test with the Bonferroni correction was
used for comparison between individual groups. A value
at P < 0.05 was considered to be significant.
RESULTS
Body weight, plasma glucose, and urinary protein
excretion of OLETF and LETO rats
Functional findings of body weight, plasma glucose,
and urinary protein excretion of OLETF and LETO
rats at 52 weeks of age are shown in Table 1. The body
weights of OLETF rats were significantly higher than
those of LETO rats. In addition, plasma levels of glu-
cose in OLETF rats were 2.3-fold higher than those of
LETO rats. Urinary protein excretion was significantly
increased in OLETF rats compared to LETO rats. These
results are consistent with previous findings [22, 23] and
OLETF rats at 52 weeks of age were observed to be char-
acteristic of diabetic nephropathy.
Table 1. Characteristics of Long Evans Tokushima Otsuka (LETO)
and Otsuka Long Evans Tokushima Fatty (OLETF) rats at 52 weeks
of age
LETO OLETF
(N = 12) (N = 11)
Body weight g 534 ± 9 614 ± 18a
Blood glucose mg/dL 66 ± 9 152 ± 26a
Urinary protein excretion lg/day 7.0 ± 1.4 67.5 ± 15.2a
Data are mean ± SD. aP < 0.01 vs. LETO rats.
Activation of BMK1 in the glomeruli of OLETF rats
As shown in Figure 1A (a and b), immunofluorescence
staining of the glomeruli revealed that BMK1 was acti-
vated in OLETF rats compared to the control LETO rats.
Histologic examination with PAS staining also showed
a marked mesangial cell proliferation and ECM ac-
cumulation in the glomeruli of OLETF rats [Fig. 1A
(c and d)]. There was a significant increase of glomeru-
lar hypercellularity and matrix score in the glomeruli of
OLETF rats compared with those of LETO rats (68 ±
2.2 cells/glomerulus vs. 47 ± 0.4 cells/glomerulus; 1.8 ±
0.07 cells/glomerulus vs. 0.32 ± 0.07 cells/glomerulus,
P < 0.05, respectively) (Fig. 1B and C). BMK1 activity
of the renal cortex was measured by immunoprecipita-
tion kinase assay and ERK1/2 and p38 activities of the
renal cortex were measured by Western blot analysis as
described in the Methods section (Fig. 2A). BMK1 and
ERK1/2 activity of the renal cortex was higher in OLETF
rats than LETO rats. However, no activation of p38 was
observed in the renal cortex of OLETF rats, in contrast
to LETO rats. Consistent with the results of immunoflu-
orescence staining, BMK1 activity was increased in the
renal cortex of OLETF rats (Fig. 2).
High glucose-induced BMK1 activation in rat
mesangial cells
It was reported that BMK1 activation was induced by
high concentrations of sorbitol in rat vascular smooth
muscle cells and bovine aortic endothelial cells [24, 25].
No studies have been published regarding the changes in
BMK1 activity in response to high glucose stimulation in
rat mesangial cells. To confirm the above in vivo findings,
we next examined whether BMK1 is activated by high
glucose in rat mesangial cells. Growth-arrested rat mesan-
gial cells were treated for various times and with different
concentrations of glucose. For comparison, the effects of
various concentrations of raffinose were also examined.
Raffinose is a trisaccharide that, unlike glucose, is unable
to enter the cell and thus exerts an osmotic effect [26].
In the examined concentration range (5.5 to 35.5 mmol/L
glucose), the BMK1 activity increased with a bell-shaped
response curve, and maximal activation occurred at a glu-
cose concentration of 15.5 mmol/L in the medium (Fig. 3).
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Fig. 1. Big mitogen-activated protein (MAP) kinase 1 (BMK1) is activated in the glomeruli of Otsuka Long Evans Tokushimas Fatty (OLETF) rats.
Immunofluorescence staining (IF) for phospho-BMK1/extracellular signal-regulated kinase (ERK) 5 in kidney section from Long Evans Tokushima
Otsuka (LETO) rats (A, a) and OLETF rats (A, b) (original magnification, ×200). Periodic acid-Schiff (PAS) staining of glomeruli from LETO rats
(A, c) and OLETF rats (A, d) (original magnification, ×200). Quantitation of glomerular hypercellularity (B) and mesangial matrix accumulation
(C). Data are shown as means ± SD The asterisks indicate significant differences compared to the value of LETO rats. ∗P < 0.05.
The 20 mmol/L raffinose incubation with 5.5 mmol/L glu-
cose caused maximal activation of BMK1 (Fig. 3). The
15.5 mmol/L glucose treatment of cells resulted in a max-
imal activation of BMK1 at 30 minutes (Fig. 4). The ef-
fect of 20 mmol/L raffinose on BMK1 activity peaked at
20 minutes and this activation was transient (Fig. 4).
Involvement of MEK5 in BMK1 activation by high
glucose exposure
Recently, MEK1/2 inhibitors, U0126 and PD98059,
were reported to inhibit MEK5, which is known as an
upstream regulator of BMK1 in various cells [17, 27]. We
also reported that H2O2-induced BMK1 activation was
inhibited by preincubation with U0126 and PD98059 in
PC 12 cells [21]. Thus, we examined whether U0126 and
PD98059 are able to inhibit BMK1 activation induced by
high glucose in rat mesangial cells. Pretreatment of rat
mesangial cells with U0126 inhibited BMK1 activation in
a concentration-dependent manner (Fig. 5A). Similar re-
sults were obtained in cells treated with another MEK1/2
inhibitor PD98059, which also inhibited BMK1 activation
by high glucose to a similar extent as U0126 (Fig. 5B).
Involvement of PKC in BMK1 activation by high glucose
Numerous studies have suggested that high glucose in-
duces activation of PKC and MAP kinase in mesangial
cells [28]. However, involvement of PKC in BMK1 ac-
tivation in rat mesangial cells has not been elucidated.
Therefore, we investigated the role of PKC in high
glucose-mediated BMK1 activation. To determine the
participation of PKC in BMK1 activation by high glucose,
cells were pretreated for 60 minutes with the specific PKC
inhibitor, GF109203X (Fig. 6A). For the down-regulation
of PKC, rat mesangial cells were treated with the phorbol
ester PMA for 24 hours. GF109203X showed signifi-
cant inhibition of BMK1 activation in a concentration-
dependent manner (Fig. 6A). The down-regulation of
PKC by PMA treatment for 24 hours also effectively
abolished the BMK1 activation by high glucose in rat
mesangial cells (Fig. 6B).
Involvement of c-Src tyrosine kinase in BMK1 activation
by high glucose exposure
Previous studies reported that c-Src is involved in
BMK1 activation by oxidative stress [21, 29]. Thus, we
examined whether c-Src mediates high glucose-induced
BMK1 activation in rat mesangial cells. As shown in
Figure 7, pretreatment with a tyrosine kinase inhibitor,
herbimycin A (Fig. 7A) or Src kinase inhibitor, PP2
(Fig. 7B), both inhibited high glucose-induced BMK1 ac-
tivation in a concentration-dependent manner.
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Fig. 2. Big mitogen-activated protein (MAP) kinase 1 (BMK1) is ac-
tivated in the renal cortex of Otsuka Long Evans Tokushima Fatty
(OLETF) rats. (A) The activities of BMK1, extracellular signal-
regulated kinase (ERK) 1/2 and p38 in the renal cortex of Long Evans
Tokushima Otsuka (LETO) rats and OLETF rats. BMK1 activity was
measured by immunoprecipitation (IP) kinase assay as described in the
Methods section. ERK1/2 and p38 activities were measured by West-
ern blot [immunoblot (IB)] analysis in the Methods section. pBMK1,
pERK1/2, and pp38 represent phosphorylated form of BMK1, ERK1/2,
and p38, respectively. BMK1, ERK1/2 and p38 represent the total (phos-
phorylated and unphosphorylated) BMK1, ERK1/2, and p38, respec-
tively. (B) Densitometric analysis of phosphorylated BMK1, ERK1/2,
and p38. Bars are the means ± SD from five different specimen of renal
cortex. The asterisks indicate significant differences compared to the
value of LETO rats. ∗P < 0.05.
PKC exists upstream of c-Src tyrosine kinase for
BMK1 activation
To investigate whether PKC or c-Src exists upstream
of the other, we examined the effects of PKC inhibitors
on Src activation and the effects of Src inhibitors on PKC
activation. High glucose treatment of cells resulted in a
maximal activation of PKC at 1 minute (2.97- ± 0.22-
fold from basal activity) and Src kinase at 2 minutes
(3.81- ± 0.45-fold from basal activity). As shown in
Figure 8, both GF109203X and 24 hours PMA treat-
ment inhibited high glucose-induced Src activation
in a concentration-dependent manner. However, PKC
activation by high glucose was not affected by pretreat-
ment with Src inhibitors, herbimycin A and PP2 (data
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Fig. 3. Concentration-response curves of glucose- or raffinose-induced
big mitogen-activated protein (MAP) kinase 1 (BMK1) activation in rat
mesangial cells. Cells were stimulated with the indicated concentrations
of glucose for 30 minutes or raffinose for 20 minutes in addition to the
normal glucose (5.5 mmol/L) media for BMK1 activation. The activity
of BMK1 was measured by immunoprecipitation (IP) kinase assay or
immunoblot (IB) as described in the Methods section. BMK1 is total
BMK1 that contains phosphorylated BMK1 (pBMKI), and unphospho-
rylated BMK1. No significant differences in the amount of BMK1 were
observed in samples by Western blot analysis with anti-extracellular
signal-regulated kinase (ERK) 5 antibody. (A) Representative blots
are shown. (B) Densitometric analysis of BMK1. Bars are the means
± SD from five independent experiments. The asterisks indicate signif-
icant differences compared to the value of glucose stimulation. ∗P <
0.05; ∗∗P < 0.01.
not shown). These results suggest that PKC is upstream
of c-Src for BMK1 activation in rat mesangial cells.
Role of BMK1 activation in rat mesangial cell
proliferation induced by high glucose exposure
It was reported that mesangial cell proliferation was
augmented by high glucose exposure [30]. Since BMK1
was activated by high glucose exposure, we investigated
the role of BMK1 activation in high glucose-induced
rat mesangial cell proliferation. We examined the ef-
fects of GF109203X, PMA, herbimycin A, PP2, U0126,
and PD98059 on rat mesangial cell proliferation induced
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Fig. 4. Time course of high concentrations of
glucose- and raffinose-induced big mitogen-
activated protein (MAP) kinase 1 (BMK1) ac-
tivation in rat mesangial cells. Cells were stim-
ulated with 10 mmol/L glucose or 20 mmol/L
raffinose in addition to the normal glucose
(5.5 mmol/L) media for the indicated peri-
ods. The activity of BMK1 was measured
by immunoprecipitation (IP) kinase assay
or immunoblotting (IB) as described in the
Methods section. BMK1 is total BMK1 that
contains phosphorylated (pBMK1) and un-
phosphorylated BMK1. No significant differ-
ences in the amount of BMK1 were observed
in samples by Western blot analysis with anti-
extracellular signal-regulated kinase (ERK) 5
antibody. (A) Representative blots are shown.
(B) Densitometric analysis of BMK1. Bars are
the means ± SD from five independent exper-
iments. The asterisks indicate significant dif-
ferences compared with the value of glucose
stimulation. ∗P < 0.05; ∗∗P < 0.01.
by high glucose. Using MTT assay, cell proliferation
was evaluated as described in ‘METHODS’. As shown
in Figure 9, all these inhibitors showed concentration-
dependent inhibition of rat mesangial cell proliferation
induced by high glucose exposure.
Although we demonstrated that U0126 and PD98059
inhibited the MEK5-BMK1 pathway in rat mesangial
cells as shown in Figure 5, these drugs also inhibit MEK1/2
in various cells [31–33]. Since mesangial cell proliferation
is also facilitated by the activation of ERK1/2 [28], which
is a downstream MAP kinase of MEK1/2, involvement of
ERK1/2 in high glucose-induced rat mesangial cell prolif-
eration cannot be excluded. Thus, we utilized transfected
rat mesangial cells with CA-MEK5 and DN-MEK5 con-
structs in this set of experiments. As shown in Figure
10, transfection with DN-MEK5 inhibited BMK1 acti-
vation similar to rat mesangial cell proliferation caused
by high glucose. In addition, transfection with CA-MEK5
increased both BMK1 activity and cell proliferation even
though cells are in the normal glucose condition.
DISCUSSION
Previous studies showed that ERK1/2 and p38 were
activated in mesangial cells exposed to high glucose and
in rat glomeruli of type 1 diabetes [34, 35]. In a type 2
diabetic model, it was reported that ERK activity was
activated in the renal cortex of db/db mice as compared
to nondiabetic mice [36]. However, it is not yet docu-
mented whether BMK1 is activated in diabetic nephropa-
thy. BMK1 was originally shown to be activated by serum
or growth factors in CHO-K1 cells, NIH-3T3 cells, and
Hela cells [37, 38]. Recent studies have reported that
other stimuli, such as oxidative or osmotic stress, can
also activate BMK1 in various cell types. It was reported
that high osmotic stress with sorbitol activated BMK1 in
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Fig. 5. Effects of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK) inhibitors, U0126 and PD98059, on big
MAP kinase 1 (BMK1) activation by high glucose in rat mesangial cells. Cells were pretreated with U0126 (A) and PD98059 (B) at the indicated
concentrations for 30 minutes. Then, the cells were stimulated with 15.5 mmol/L glucose at the final concentration for 30 minutes. The activity of
BMK1 was measured using immunoprecipitation (IP) kinase or immunoblot (IB) assay as described in the Methods section. BMK1 is total BMK1
that contains phosphorylated (pBMK1) and unphosphorylated BMK1. No significant differences in the amount of BMK1 were observed in samples
by Western blot analysis with anti-extracellar signal-regulated kinase (ERK) 5 antibody (A and B, middle). Bars are the means ± SD from five
independent experiments. The asterisks indicate significant differences compared with the value of glucose stimulation. ∗P < 0.05; ∗∗P < 0.01.
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Fig. 6. Effects of protein kinase C (PKC) inhibitor, GF109203X, and down-regulation of PKC with phorbol myristate acetate (PMA) on big
mitogen-activated protein (MAP) kinase 1 (BMK1) activation by high glucose in rat mesangial cells. (A) Cells were pretreated with GF109203X at
the indicated concentrations for 60 minutes. (B) Cells were pretreated with PMA at the indicated concentrations for 24 hours. Then the cells were
stimulated with 15.5 mmol/L glucose at the final concentration for 30 minutes. The activity of BMK1 was measured by immunoprecipitation (IP)
kinase or immunblot (IB) assay as described in the Methods section. BMK1 is total BMK1 that contains phosphorylated (pBMK1) and unphos-
phorylated BMK1. No significant differences in the amount of BMK1 were observed in samples by Western blot analysis with anti-extracellular
signal-regulated kinase (ERK) 5 antibody (A and B, middle). Bars are the means ± SD from five independent experiments. The asterisks indicate
significant differences compared with the value of 15.5 mmol/L glucose stimulation. ∗P < 0.05; ∗∗P < 0.01.
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Fig. 7. Effects of Src inhibitors, herbimycin A and PP2, on big mitogen-activated protein (MAP) kinase 1 (BMK1) activation by high glucose
in rat mesangial cells. Cells were pretreated with herbimycin A for 16 hours (A) and PP2 for 15 minutes (B) at the indicated concentrations.
Then, the cells were stimulated with 15.5 mmol/L glucose at the final concentration for 30 minutes. The activity of BMK1 was measured by
immunoprecipitation (IP) kinase or immunoblot (IB) assay as described in the Methods section. BMK1 is total BMK1 that contains phosphorylated
(pBMK1) and unphosphorylated BMK1. No significant differences in the amount of BMK1 were observed in samples by Western blot analysis with
anti-extracellular signal-regulated kinase (ERK) 5 antibody (A and B, middle). Bars are the means ± SD from five independent experiments. The
asterisks indicate significant differences compared with the value of 15.5 mmol/L glucose stimulation. ∗P < 0.05; ∗∗P < 0.01.
vascular endothelial cells [25]. It was also reported that
sorbitol activated BMK1 in vascular smooth muscle cells
[39]. Therefore, we hypothesized that BMK1 may be acti-
vated in the glomeruli of diabetic rat model. OLETF rats
are a newly developed model of human type 2 diabetes
mellitus and show a character of diabetic nephropathy
in elderly [40]. As shown in Figure 1, we observed that
BMK1 was activated in the glomeruli of 52 weeks age of
OLETF rats, whereas no significant activation of BMK1
was observed in the control LETO rats. Quantification
of mesangial hypecellularity and matrix score revealed
the glomerular injury in OLETF rats (Fig. 1B and C).
Western blot analysis of renal cortex protein showed an
increase in BMK1 and ERK1/2 activities but not p38 in
OLETF rats (Fig. 2A and B).
To confirm this further, we examined the effect of high
glucose on BMK1 activity in cultured rat mesangial cells.
As a result, we found for the first time that endogenous
BMK1 was rapidly and significantly activated by high
glucose levels in intact rat mesangial cells (Figs. 3 and
4). The maximal concentration-response was observed at
15.5 mmol/L glucose, which was suggested to be observed
in patients with severe diabetes mellitus. These results are
consistent with others which reported that 25 mmol/L
glucose caused activation of BMK1 in vascular endothe-
lial cells [26]. In addition, a trisaccharide raffinose also
activated BMK1 in rat mesangial cells (Figs. 3 and 4).
Since raffinose, unlike glucose, cannot enter the cells, the
ability of glucose to induce BMK1 activation may be at-
tributable to the osmotic effect. However, since the time
course and the concentration-response were not similar
between glucose and raffinose, involvement of mecha-
nisms other than osmotic stress cannot be denied in high
glucose-induced BMK1 activation.
The intracellular signaling mechanisms that lead to
BMK1 activation have been investigated. Using the yeast
two-hybrid system, MEK5 was identified by Zhou, Bao,
and Dixon [13] as the molecule responsible for regulating
BMK1 activity. Kato et al [37] reported that MEK5 specif-
ically activated BMK1 but not other mammalian MAP
kinases in vivo [37]. Therefore, we examined whether
MEK5 is involved in the BMK1 activation by high glu-
cose in rat mesangial cells. We utilized MEK1/2 inhibitors,
U0126 and PD98059, which were also reported to in-
hibit MEK5 in various cells [17, 41]. Although it was
reported that higher concentration of these inhibitors
is needed to suppress MEK5 than to inhibit MEK1/2,
pretreatment of the cells with both U0126 and PD98059
resulted in an inhibition of BMK1 activation by high glu-
cose in a concentration-dependent manner (Fig. 5). These
results suggest that MEK5 is responsible for high glucose-
induced BMK1 activation.
In the glomeruli of diabetic nephropathy, numerous
studies have reported the importance of PKC [28]. It
was reported that MEK5 is a critical target of atypical
PKC in mitogenic signaling [42]. It was also reported that
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Fig. 8. Effects of protein kinase C (PKC) inhibitor, GF109203X, and down-regulation of PKC with phorbol myristate acetate (PMA) on c-Src
activation by high glucose in rat mesangial cells. (A) Cells were pretreated with GF109203X at the indicated concentrations for 30 minutes. (B)
Cells were pretreated with PMA at the indicated concentrations for 24 hours. Then the cells were stimulated with 15.5 mmol/L glucose at the final
concentration for 2 minutes. The activity of c-Src was measured by Western blot analysis [immunoblot (IB)] with phospho-Src antibody as described
in the Methods section. pY418 Src is phosphorylated Src. c-Src is total Src that contains phosphorylated and unphosphorylated Src. No significant
differences in the amount of Src were observed in samples by Western blot analysis with anti-Src antibody (A and B, middle). Bars are the means ±
SD from five independent experiments. The asterisks indicate significant differences compared with the value of 15.5 mmol/L glucose stimulation.
∗P < 0.05; ∗∗P < 0.01.
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Fig. 9. Effects of protein kinase C (PKC) in-
hibitors, Src inhibitors, and mitogen-activated
protein kinase/extracellular signal-regulated
kinase kinase (MEK) inhibitors on rat mesan-
gial cell proliferation by high glucose. Cells
were pretreated with phorbol myristate ac-
etate (PMA) at the indicated concentration
for 24 hours. Cells were pretreated with
GF109203X (GF), U0126 and PD98059 for 30
minutes, herbimycin A (HA) for 16 hours, and
PP2 for 15 minutes at the indicated concentra-
tions. After the addition of these inhibitors,
cells were treated with 5.5 mmol/L glucose or
15.5 mmol/L glucose for 48 hours. Cell pro-
liferation was evaluated by methyl-thiazolyl
tertrazolium (MTT) reduction as described in
the Methods section. Values are the means ±
SD of five experiments performed in tripli-
cate. The asterisks indicate significant differ-
ences compared with the value of 15.5 mmol/L
glucose stimulation. ∗P < 0.05; ∗∗P < 0.01.
granulocyte colony-stimulating factor-induced BMK1 ac-
tivation is regulated by PKC [43]. We found in the present
study that PKC inhibition by GF109203X or PKC de-
pletion by PMA exposure for 24 hours both inhibited
high glucose-induced BMK1 activation (Fig. 6). Since
PKC-dependent ERK1/2 activation in mesangial cells is
well documented [34], BMK1 activation may also be de-
pendent on PKC. Although the involvement of PKC in
BMK1 activation was suggested, the molecule(s) respon-
sible for PKC activation are still unknown. Since PKC was
shown to be sensitive to ROS [44], ROS may be involved
in this process.
In addition to PKC, c-Src tyrosine kinase may also be
involved in BMK1 activation and c-Src was reported to
be sensitive to ROS. c-Src-mediated BMK1 activation
in response to oxidative stress in fibroblasts was also
reported [29]. In addition, we previously observed that
H2O2-induced BMK1 activation was c-Src-dependent
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Fig. 10. Transfection with dominant-negative mitogen-activated pro-
tein kinase (MAP)/extracellular signal-regulated kinase kinase 5 (DN-
MEK5) abolished the big MAP kinase 1 (BMK1) activation and prolif-
eration of rat mesangial cells, whereas constitutive-active MEK5 (CA-
MEK5) transfection increased BMK1 activation and cell proliferation
even though cells were in the normal glucose condition. Cells were
transfected with empty vector (pcDL-SRa), DN-MEK5, or CA-MEK5
and 5 hours later washed and maintained with normal medium. The
activity of BMK1 was measured by immunoprecipitation (IP) kinase
or immunoblot (IB) assay as described in the Methods section. BMK1
is total BMK1 that contains phosphorylated (pBMK1) and unphos-
phorylated BMK1. (A) Representative blots of BMK1 activation are
shown. After 24 hours, cells were moved to serum-free media then the
cells were stimulated with 15.5 mmol/L glucose at the final concentra-
tion for 30 minutes. (B) Results of rat mesangial cells proliferation are
shown. After transfection, cells were treated with 5.5 mmol/L glucose
or 15.5 mmol/L glucose for 48 hours. Cell proliferation was evaluated
by methyl-thiazolyl tertrazolium (MTT) reduction as described in the
Methods section. Values are the means ± SD of five experiments per-
formed in triplicate. The asterisks indicate significant differences com-
pared with the value of the cells transfected with the empty vector alone.
∗P < 0.05; ∗∗P < 0.01.
in PC12 cells [21]. Therefore, in the present study, we
examined whether or not c-Src mediates high glucose-
induced BMK1 activation. As shown in Figure 7, specific
inhibitors of Src family tyrosine kinases, herbimycin A
and PP2, both inhibited high glucose-induced BMK1 ac-
tivation in a concentration-dependent manner. Consis-
tent with the present findings, tyrosine kinase-dependent
BMK1 activation was also reported [43]. However, since
we did not determine whether c-Src directly regulates
MEK5 activity in this study, further studies are required
to define the precise nature of Src kinases in BMK1 ac-
tivation. In addition, we investigated which molecule is
upstream. Although Src inhibitors failed to inhibit PKC
activation by high glucose, PKC inhibitors significantly in-
hibited high glucose-induced Src activation in rat mesan-
gial cells (Fig. 8). Therefore, it was suggested that PKC
exists upstream of c-Src for BMK1 activation in rat
mesangial cells.
The pathophysiologic role of BMK1 in the kidney has
not been reported. A critical role of BMK1 for S-phase
entry in the cell cycle has been reported [38]. It was also
reported that BMK1 is important for vascular smooth
muscle proliferation [39] and skeletal muscle differentia-
tion [45]. Thus, we investigated the involvement of BMK1
activation in rat mesangial cell proliferation induced by
high glucose levels. All inhibitors examined, such as PKC
inhibitors, Src inhibitors and MEK inhibitors, abolished
rat mesangial cell proliferation induced by high glucose
(Fig. 9). In addition, transfection with DN-MEK5 inhib-
ited BMK1 activation similar to rat mesangial cell prolif-
eration caused by high glucose levels, though transfection
with CA-MEK5 increased both BMK1 activity and cell
proliferation even though the condition was a normal glu-
cose concentration (Fig. 10). In addition to the results of
immunohistochemistry in the glomeruli of OLETF rats,
these results suggest that BMK1 has a role in the pro-
liferation of rat mesangial cells induced by high glucose
levels. Since accumulating evidence suggests that mesan-
gial cell proliferation is one of the causative factors for
progression of diabetes nephropathy [9, 28], BMK1 may
be another possible candidate that is involved in these
processes.
CONCLUSION
We showed for the first time that BMK1 is activated
by high glucose levels both in in vivo and in vitro. As
signaling molecules, PKC and c-Src were suggested to
be involved in high glucose-induced BMK1 activation.
Although the pathophysiologic role of BMK1 in diabetic
nephropathy still remains to be elucidated, it may be an
alternative candidate for its cause.
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